Angiotech Pursues Peripheral DES Deal With Cook, Boston Scientific
This article was originally published in The Pink Sheet Daily
Executive Summary
Boston Scientific, Cook and Angiotech are close to finalizing a three-way pact for development of peripheral drug-eluting stents. The deal would allow Cook and Boston Scientific to use paclitaxel for the peripheral stents.